Pharma AI Tracker

Genmab's 2024 annual report describes a partnership with ChatGPT to launch AI Everywhere, so that more than 2,000 colleagues can use ChatGPT.

Partners: ChatGPT

Novo uses AI to find subpopulations, improve trial design and site selection, and forecast outcomes, drawing on harmonized data from about 1,600 trials.

Novo combined AI with high-throughput experiments to assess one billion virtual molecules. The work led to a selective amylin compound.

Teva describes ToMoTo, its topic-modeling tool, as artificial intelligence software that searches medical-affairs databases and compiles a report within three to five minutes.

Daiichi Sankyo said on January 21, 2025 that it had established a San Diego laboratory dedicated to robotics, automation and software for drug discovery. The release says the laboratory will collect data so discovery work can draw on AI, and so scientists can use analytical tools that are based on AI.

Merck's data science and RWE groups agreed to use Atropos Health's platform and services to generate real-world evidence faster.

Partners: Atropos Health

Sanofi's pharmacovigilance team uses AI and OCR on the IQVIA Vigilance Platform to automate intake of the more than 700,000 adverse reactions it receives each year.

Partners: IQVIA

Takeda's medical writing team built a generative AI prototype to speed compilation of regulatory dossiers by automating analysis of clinical study data. It was being tested on a CSR efficacy section.

Bayer's AI Innovation Platform is a cloud platform, built on Google Cloud, for developing imaging AI and machine-learning healthcare applications. Bayer says it is in external testing.

Partners: Google Cloud

Bayer says Calantic Digital Solutions offers AI-enabled applications that are already available and cleared, orchestrated on one platform for everyday clinical tasks.

MSD worked with the AWS Generative AI Innovation Center on a tool that turns plain-language questions into SQL queries against complex healthcare datasets.

Partners: AWS

Immunai announced a multi-year collaboration with Teva in immunology and immuno-oncology. Immunai says the work will use its AI model, the Immunodynamics Engine, for clinical-trial decisions including mechanism of action, dose selection and biomarker analyses.

Partners: Immunai

An AI tool built jointly by Formation Bio, OpenAI and Sanofi to speed up patient recruitment for clinical trials. Sanofi planned the first deployment in Phase 3 multiple sclerosis studies.

Partners: Formation Bio, OpenAI

BMS describes private in-house ChatGPT and GenAI tools that employees use to upload documents, summarize information, plan projects and find company information.

BMS describes MyGrowth, an AI-enabled internal talent marketplace that matches employees with roles, projects and learning recommendations.

BMS says it uses reinforcement AI to deliver personalized content to physicians through digital channels.

Merck runs an in-house, secured generative AI workspace called GPTeal that gives employees access to several large language models. The CIDO described broad staff adoption in an interview.

Partners: OpenAI, Meta, Anthropic

J&J applies machine learning to large de-identified datasets to find trial sites with eligible patients and to make enrollment faster and more representative.

Engagement.ai is J&J's global machine learning capability that guides when, where and how the company engages healthcare professionals.

J&J analyses demand swings, supplier performance and other data with machine learning to anticipate events that could disrupt product supply.

At its AI Day, BioNTech highlighted InstaDeep's new near-exascale supercomputer, Kyber, with the aim of enabling BioNTech to compute at scale. The release describes this as the introduction of a new near-exascale supercomputer.

At the same AI Day, BioNTech unveiled novel AI Bayesian Flow Network models for protein sequence generation. The release describes the update as the launch of a novel BFN generative model.

InstaDeep's chief executive, speaking as part of BioNTech's AI Day, said a key focus is the DeepChain multiomics design platform. He said DeepChain is now open for external partnerships after successful application to several projects, including the mRNA-encoded antibody RiboMab platform.

BioNTech's AI Day release says the company is highlighting progress in deploying AI across its immunotherapy pipeline, including immunohistochemistry, DNA and RNA sequencing, proteomics, protein design and laboratory functional validation.

AbbVie says large language models let researchers engineer drug candidates in silico rather than relying solely on high-throughput screening.